Erratum: Thakur A, Kadam RS, and Kompella UB (2011) Influence of Drug Solubility and Lipophilicity on Transscleral Retinal Delivery of Six Corticosteroids. Drug Metab Dispos(Drug Metabolism and Disposition (2011) 39 (771-781) Doi:10.1124/dmd.110.037408);Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 771-781

  Thakur, Ashish ^a,c   Kadam, Rajendra S ^a   Kompella, Uday B ^a,b,c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PREDNISOLONE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; SCLERA; SUSPENSION; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; VITREOUS BODY;

BOVINAE; RATTUS NORVEGICUS;

EID: 79955045075     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037408     Document Type: Erratum

References (32)

1. Adelman RA, Zheng Q, and Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105-110.
2. Amrite AC, Ayalasomayajula SP, Cheruvu NP, and Kompella UB (2006) Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 47:1149-1160. (Pubitemid 46768351)
3. Amrite AC, Edelhauser HF, and Kompella UB (2008a) Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci 49:320-332.
4. Amrite AC, Edelhauser HF, Singh SR, and Kompella UB (2008b) Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis 14:150-160. (Pubitemid 351194002)
5. Amrite AC and Kompella UB (2005) Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 57:1555-1563. (Pubitemid 41752269)
6. Ayalasomayajula SP and Kompella UB (2004) Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 21:1797-1804. (Pubitemid 39390091)
7. Ayalasomayajula SP and Kompella UB (2005) Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 511:191-198. (Pubitemid 40417726)
8. Cheruvu NP, Amrite AC, and Kompella UB (2008) Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci 49:333-341.
9. Cheruvu NP and Kompella UB (2006) Bovine and porcine transscleral solute transport: Influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci 47:4513-4522. (Pubitemid 46579380)
10. Cruysberg LP, Nuijts RM, Geroski DH, Koole LH, Hendrikse F, and Edelhauser HF (2002) In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexatefluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther 18:559-569. (Pubitemid 36020257)
11. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, et al. (2003) Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelve-month clinical outcomes. Ophthalmology 110:2372-2383; discussion 2484-2485.
12. Dahlin DC and Rahimy MH (2007) Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol 52 (Suppl 1):S49-S61. (Pubitemid 46107521)
13. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, and Kompella UB (2009) Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci 50:4887-4897.
14. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, et al. (2010) Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications. Invest Ophthalmol Vis Sci 51:5403-5420.
15. Kadam RS, Cheruvu NP, Edelhauser HF, and Kompella UB (2011) Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6233.
16. Kadam RS and Kompella UB (2010) Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther 332:1107-1120.
17. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, and Csaky KG (2004) Controlled drug release from an ocular implant: An evaluation using dynamic threedimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 45:2722-2731. (Pubitemid 38998870)
18. Kompella UB (2007) Drug delivery to the back of the eye. Arch Soc Esp Oftalmol 82:667-668; 669-670.
19. Kompella UB, Kadam RS, and Lee VH (2010) Recent advances in ophthalmic drug delivery. Ther Deliv 1:435-456.
20. Kumar V and Tewari D (2005) Dissolution, in Remington: The Science and Practice of Pharmacy, 21st ed (Troy DB ed) pp 495-672, Lippincott Williams & Wilkins, Baltimore.
21. Leblanc B, Jezequel S, Davies T, Hanton G, and Taradach C (1998) Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 28:124-132. (Pubitemid 29076778)
22. Lin JM, Chiu YT, Hung PT, and Tsai YY (2007) Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide. Retina 27:180-189.
23. Missel PJ, Stevens LE, and Mauger JW (2004) Dissolution of anecortave acetate in a cylindrical flow cell: Re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs. Pharm Dev Technol 9:453-459. (Pubitemid 39525268)
24. Raghava S, Hammond M, and Kompella UB (2004) Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 1:99-114. (Pubitemid 40297959)
25. Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, and Kompella UB (2010) Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci 51:5198-5204.
26. Sampat KM and Garg SJ (2010) Complications of intravitreal injections. Curr Opin Ophthalmol 21:178-183.
27. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, Oyagi T, and Sawada K (2010) Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 117:512-516, 516.e1-516.e2.
28. Shima C, Ogata N, Minamino K, Yoshikawa T, Yoshikawa T, Matsuyama K, and Matsumura M (2008) Posterior sub-Tenon injection of triamcinolone acetonide as pretreatment for focal laser photocoagulation in diabetic macular edema patients. Jpn J Ophthalmol 52:265-268.
29. Thakur A, Kadam RS, and Kompella UB (2010) Trabecular meshwork and lens partitioning of corticosteroids: Implications for elevated intraocular pressure and cataracts. Arch Ophthalmol doi:10.1001/ archophthalmol.2011.39.
30. Toda J, Fukushima H, and Kato S (2007) Injection of triamcinolone acetonide into the posterior sub-tenon capsule for treatment of diabetic macular edema. Retina 27:764-769. (Pubitemid 47051774)
31. Tsujikawa A, Fujihara M, Iwawaki T, Yamamoto K, and Kurimoto Y (2005) Triamcinolone acetonide with vitrectomy for treatment of macular edema associated with branch retinal vein occlusion. Retina 25:861-867. (Pubitemid 41456577)
32. U.S. Environmental Protection Agency (1982) Partition coefficient CG 1400, in Chemical fate testing guidelines, EPA 560/6-82-003, National Technical Information Services, Springfield, VA.